Your browser is no longer supported. Please, upgrade your browser.
Settings
XENE Xenon Pharmaceuticals Inc. daily Stock Chart
XENE [NASD]
Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own2.10% Shs Outstand27.25M Perf Week-4.80%
Market Cap361.88M Forward P/E- EPS next Y-1.95 Insider Trans-5.97% Shs Float24.94M Perf Month46.09%
Income-37.30M PEG- EPS next Q-0.49 Inst Own76.10% Short Float3.05% Perf Quarter40.68%
Sales3.50M P/S103.39 EPS this Y4.70% Inst Trans0.93% Short Ratio6.89 Perf Half Y42.34%
Book/sh2.59 P/B5.13 EPS next Y-52.30% ROA-33.70% Target Price21.75 Perf Year90.80%
Cash/sh3.47 P/C3.83 EPS next 5Y- ROE-46.30% 52W Range5.41 - 14.95 Perf YTD110.46%
Dividend- P/FCF- EPS past 5Y-50.60% ROI- 52W High-11.17% Beta1.50
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low145.47% ATR0.89
Employees89 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)62.42 Volatility7.66% 8.32%
OptionableYes Debt/Eq0.23 EPS Q/Q47.30% Profit Margin- Rel Volume0.82 Prev Close13.99
ShortableYes LT Debt/Eq0.18 EarningsNov 05 AMC Payout- Avg Volume110.36K Price13.28
Recom1.20 SMA2014.18% SMA5034.14% SMA20038.39% Volume90,318 Change-5.08%
Sep-20-19Initiated Guggenheim Buy $25
Aug-08-18Reiterated Stifel Buy $9 → $15
Mar-13-17Initiated Jefferies Buy $13
Oct-21-16Initiated Stifel Buy $18
Sep-26-16Initiated Guggenheim Buy $20
Apr-14-16Reiterated Jefferies Buy $10 → $13
Oct-30-15Resumed Jefferies Buy
Dec-02-14Initiated Canaccord Genuity Buy $15
Dec-11-19 11:23AM  Did Hedge Funds Drop The Ball On Xenon Pharmaceuticals Inc (XENE) ? Insider Monkey -8.81%
Dec-07-19 08:45AM  Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-06-19 08:45AM  Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-03-19 05:23PM  Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire +10.32%
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 07:45AM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences GlobeNewswire
07:30AM  Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy GlobeNewswire
Nov-21-19 09:44AM  Edited Transcript of XENE earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-19 08:45AM  Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-11-19 09:45AM  Is Xenon Pharmaceuticals Inc (XENE) A Good Stock To Buy? Insider Monkey
Nov-05-19 04:01PM  Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-29-19 04:30PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Oct-25-19 02:20PM  Volatility 101: Should Xenon Pharmaceuticals (NASDAQ:XENE) Shares Have Dropped 18%? Simply Wall St.
Oct-16-19 08:30AM  Encode Ideas, L.P. Announces the Initiation of Research Coverage on Xenon Pharmaceuticals Inc. Newsfile
Oct-01-19 07:21AM  Xenon Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-25-19 04:05PM  Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
11:49AM  Have Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Insiders Been Selling Their Stock? Simply Wall St.
Sep-24-19 09:36AM  Does The Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Share Price Fall With The Market? Simply Wall St.
Sep-17-19 04:05PM  Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources GlobeNewswire
Sep-09-19 04:01PM  Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexions Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain GlobeNewswire
Sep-05-19 11:22AM  Edited Transcript of XENE earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 12:51PM  Is Xenon Pharmaceuticals (NASDAQ:XENE) Using Too Much Debt? Simply Wall St.
Aug-06-19 09:33PM  Xenon Pharmaceuticals Inc. (XENE) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Jul-09-19 11:11AM  Do Institutions Own Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? Simply Wall St.
Jun-14-19 06:55PM  Hedge Funds Have Never Been This Bullish On Xenon Pharmaceuticals Inc (XENE) Insider Monkey
Jun-05-19 08:10AM  Xenon Pharmaceuticals Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference GlobeNewswire
Jun-03-19 05:58PM  Edited Transcript of XENE earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-29-19 04:19PM  Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-21-19 03:18PM  Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Overpaying Its CEO? Simply Wall St. +6.03%
May-15-19 12:31PM  Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 05:19PM  Xenon Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:01PM  Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-30-19 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Apr-24-19 04:01PM  Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
Apr-04-19 09:00AM  Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Immense Growth Potential? Simply Wall St.
Mar-13-19 02:02AM  Edited Transcript of XENE earnings conference call or presentation 6-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 04:01PM  Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Xenon Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
07:39AM  The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split Benzinga
Feb-27-19 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update GlobeNewswire +7.42%
Feb-26-19 07:30AM  Behind the Seizure Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures PR Newswire
Jan-28-19 08:00AM  Xenon Provides Key Regulatory Updates on XEN007 and XEN1101 GlobeNewswire
Jan-18-19 12:24PM  What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock? Simply Wall St.
Jan-06-19 09:00PM  Xenon Pharmaceuticals Outlines 2019 Key Milestones GlobeNewswire
Dec-26-18 02:14PM  Eversept Partners Return, AUM, and Holdings Insider Monkey
Dec-19-18 01:54AM  Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-18 07:30AM  Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Nov-30-18 09:00AM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting GlobeNewswire +5.51%
Nov-19-18 01:51PM  Edited Transcript of XENE earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 11:56AM  Granite Point Capitals Returns, AUM, and Holdings Insider Monkey
Nov-15-18 09:41AM  Is Xenon Pharmaceuticals Inc (NASDAQ:XENE) Overpaying Its CEO? Simply Wall St.
07:55AM  Investor Expectations to Drive Momentum within The York Water, Canon, Peak Resorts, Volt Information Sciences, LSI Industries, and Xenon Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-07-18 04:02PM  Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
05:17AM  Xenon Pharmaceuticals: 3Q Earnings Snapshot Associated Press
Nov-06-18 04:01PM  Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-30-18 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire
Oct-12-18 08:27AM  The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena Zacks
Oct-11-18 09:24AM  4 Healthcare Stocks Thriving on Venture Capital Funding Zacks
Sep-17-18 04:15PM  Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares GlobeNewswire
Sep-12-18 08:15PM  Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares GlobeNewswire
04:01PM  Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares GlobeNewswire
01:56PM  Breakeven On The Horizon For Xenon Pharmaceuticals Inc (NASDAQ:XENE) Simply Wall St.
Sep-11-18 08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
Sep-10-18 09:17PM  Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program GlobeNewswire
Sep-06-18 06:30AM  Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a Phase 3 Ready Potassium Channel Modulator for the Treatment of Epilepsy GlobeNewswire
Aug-31-18 08:29AM  The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage Benzinga
Aug-29-18 06:05AM  Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study GlobeNewswire
Aug-26-18 03:40PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results Benzinga
Aug-21-18 01:39AM  Edited Transcript of XENE earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-18 06:35PM  Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates Zacks
05:28PM  Xenon Pharmaceuticals: 2Q Earnings Snapshot Associated Press
04:01PM  Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 08:58AM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
Jul-25-18 07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-12-18 07:00AM  Xenon Pharmaceuticals Announces At-The-Market Equity Offering GlobeNewswire +7.22%
Jun-08-18 06:14PM  Edited Transcript of XENE earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-18 04:01PM  Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
May-17-18 07:10AM  Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference ACCESSWIRE
May-15-18 06:10AM  Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference GlobeNewswire +10.83%
06:05AM  Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference GlobeNewswire
May-14-18 04:46PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference GlobeNewswire
May-13-18 10:06AM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
May-08-18 06:17PM  Xenon Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:02PM  Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-01-18 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire
Apr-25-18 04:01PM  Xenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
Mar-28-18 08:30AM  Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P. GlobeNewswire
Mar-13-18 04:05PM  Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer GlobeNewswire
Mar-08-18 08:48AM  Edited Transcript of XENE earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-18 04:01PM  Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update GlobeNewswire +6.17%
12:15PM  Xenon Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
09:58AM  Xenon Pharmaceuticals Q4 Earnings Outlook Benzinga
Feb-28-18 04:03PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update GlobeNewswire
Feb-20-18 08:30AM  Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial GlobeNewswire
Jan-08-18 08:30AM  Xenon Pharmaceuticals Outlines Key Milestones for 2018 GlobeNewswire
Dec-04-17 04:01PM  Positive Preclinical Data from Xenons XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting GlobeNewswire
Nov-09-17 09:44AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-08-17 04:01PM  Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference GlobeNewswire
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATOU GARYDirectorDec 04Option Exercise3.562,0577,32321,516Dec 06 05:12 PM
TARNOW MICHAEL MDirectorNov 21Option Exercise3.557,20125,53369,713Nov 22 01:30 PM
HOLLER FRANK ADirectorSep 20Sale9.395,20648,884118,955Sep 20 04:15 PM
PIMSTONE SIMON N.CEOSep 20Sale9.5110,39598,856258,122Sep 24 06:14 PM
HOLLER FRANK ADirectorSep 19Sale9.277,60070,452124,161Sep 20 04:15 PM
HOLLER FRANK ADirectorSep 18Sale9.284,36840,535131,761Sep 18 06:43 PM
PIMSTONE SIMON N.CEOSep 17Option Exercise3.5357,612203,381272,209Sep 18 07:06 PM
HOLLER FRANK ADirectorSep 17Sale9.325,06947,243136,129Sep 18 06:43 PM
AZAB MOHAMMADDirectorSep 13Sale9.312321457,561Sep 17 04:46 PM
HOLLER FRANK ADirectorSep 12Option Exercise3.0731,89298,052148,979Sep 13 08:13 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationSep 12Option Exercise3.076,17218,94812,064Sep 13 06:58 PM
TARNOW MICHAEL MDirectorMay 21Option Exercise3.212,0576,60364,569May 23 11:56 AM
Hayden Michael RDirectorMar 19Option Exercise3.3820,57669,54750,924Mar 20 05:13 PM